An update on the diagnosis and treatment of Parkinson disease
- PMID: 27221269
- PMCID: PMC5088077
- DOI: 10.1503/cmaj.151179
An update on the diagnosis and treatment of Parkinson disease
Conflict of interest statement
Mandar Jog reports honoraria from Merz Pharmaceuticals, Allergan and AbbVie; and grants from the Canadian Institutes of Health Research, Academic Medical Organization of Southwestern Ontario, Lawson Health Research Institute, AGE-WELL Networks of Centres of Excellence, Merz Pharmaceuticals and Boston Scientific. He occasionally serves on advisory boards of Allergan, Boston Scientific, AbbVie and Merz Pharmaceuticals. No other competing interests were declared.
Similar articles
-
Levodopa-carbidopa intestinal gel therapy after deep brain stimulation.Mov Disord. 2018 Feb;33(2):334-335. doi: 10.1002/mds.27211. Epub 2017 Nov 6. Mov Disord. 2018. PMID: 29105810 No abstract available.
-
New and emerging treatments for Parkinson disease.Med J Aust. 2015 Apr 6;202(6):283-4. doi: 10.5694/mja15.00155. Med J Aust. 2015. PMID: 25832138 No abstract available.
-
Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease.Mov Disord. 2011 Mar;26(4):664-70. doi: 10.1002/mds.23524. Epub 2011 Apr 5. Mov Disord. 2011. PMID: 21469197
-
Diagnosis and Treatment of Parkinson Disease: A Review.JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. JAMA. 2020. PMID: 32044947 Review.
-
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.Pract Neurol. 2013 Jun;13(3):140-52. doi: 10.1136/practneurol-2012-000463. Epub 2013 Mar 13. Pract Neurol. 2013. PMID: 23487815 Review.
Cited by
-
Metabolic profiling reveals circulating biomarkers associated with incident and prevalent Parkinson's disease.NPJ Parkinsons Dis. 2024 Jul 9;10(1):130. doi: 10.1038/s41531-024-00713-2. NPJ Parkinsons Dis. 2024. PMID: 38982064 Free PMC article.
-
Quinuclidine-Based Carbamates as Potential CNS Active Compounds.Pharmaceutics. 2021 Mar 20;13(3):420. doi: 10.3390/pharmaceutics13030420. Pharmaceutics. 2021. PMID: 33804719 Free PMC article.
-
MicroRNAs in the epigenetic regulation of disease progression in Parkinson's disease.Front Cell Neurosci. 2022 Sep 16;16:995997. doi: 10.3389/fncel.2022.995997. eCollection 2022. Front Cell Neurosci. 2022. PMID: 36187290 Free PMC article. Review.
-
Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis.Parkinsons Dis. 2022 Aug 30;2022:4216452. doi: 10.1155/2022/4216452. eCollection 2022. Parkinsons Dis. 2022. PMID: 36081594 Free PMC article.
-
Molecular and therapeutic insights of rapamycin: a multi-faceted drug from Streptomyces hygroscopicus.Mol Biol Rep. 2023 Apr;50(4):3815-3833. doi: 10.1007/s11033-023-08283-x. Epub 2023 Jan 25. Mol Biol Rep. 2023. PMID: 36696023 Free PMC article. Review.
References
-
- Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384–6. - PubMed
-
- Twelves D, Perkins KSM, Counsell C. Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003;18: 19–31. - PubMed
-
- de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5:525–35. - PubMed
-
- de Lau LML, Giesbergen PCLM, de Rijk MC, et al. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004;63:1240–4. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical